Author: OurCrowd

Newsletter: Game-changing tech for lab-grown food + Investing in the Metaverse

Top investment opportunitiesStartup of the Week: Mermade, game-changing tech for lab-grown foodJerusalem, Tel Aviv among world’s best Ag/FoodTech hubsNas Academy joins OurCrowd portfolioJune 20th online: Startups in the MetaverseD-ID generates the virtual presenter of your choiceSomaLogic inks licencing agreement with OncoHostFDA clears Scopio Labs’ blood test device and applicationTechCrunch: Xage Security releases advanced anti-MFA toolBloomberg: Focus on safety drives Superpedestrian’s success FDA approves Alpha Tau’s pivotal cancer studySnow Software and Anodot team up to unravel complicated cloud costsVirginia taps BlueGreen Technologies to clean up swimming lakeIntroductionsMore than 3,800 high-tech jobs Startup of the Week:Mermade: Game-changing tech for lab-grown food Many kinds of lab-grown meat haven’t come to market because they’re too expensive to produce, in large part because the nutrient-rich soup they grow in is so costly. Our portfolio company Mermade Seafoods has created a growth slurry that will drive down costs dramatically – for cultivated meat as well as seafood, Food Navigator reports. “This is a real game changer in the industry,” says Dr. Rotem Kadir, Mermade’s chief technology officer. The company is focusing its efforts on its first...

Read More

[Armory in PR Newswire] Armory launches continuous deployment-as-a-service product

SAN MATEO, Calif., June 16, 2022 /PRNewswire/ — Armory, the continuous deployment (CD) company empowering development teams to easily, reliably, safely and continuously deploy software at any scale, has announced general availability of Armory Continuous Deployment-as-a-Service. The product delivers declarative deployments across multiple environments that support advanced progressive strategies, allowing developers to focus on building great code rather than deploying it, enhancing their customers’ experience and avoiding outages. Read...

Read More

[Alpha Tau in PR Newswire] Alpha Tau announces receipt of radioactive license to allow production in main manufacturing floor at its Jerusalem site, amended radioactive license with increased capacity at Lawrence, MA site 

JERUSALEM, June 16, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that the Israeli Ministry of Environmental Protection has granted the Company an active radioactive license for use and possession of Thorium-228 and Radium-224, radioactive materials which are utilized in the production of the Alpha DaRT sources, in the main manufacturing floor of the Company’s production facility in Jerusalem. Read...

Read More